This article was originally published in The Rose Sheet
Executive SummaryTotal Care launch in the UK, contributes to brand sales growth of 6.5% to $73.6 mil. in the first half (ended Sept. 30), Boots reports. Flat performance in the U.S. was due to inventory reductions in the trade offsetting rising consumer sales, according to the retailer. Boots Healthcare International sales increased 11.7% in the half to $381.1 mil., while operating profit was up 1.1% to $59.4 mil. Brand investment in the period was up 3% to $121.4 mil., largely due to continued investment behind Clearasil...
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.